Literature DB >> 23574716

The significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics.

Luigi Strizzi1, Naira V Margaryan, Alina Gilgur, Katharine M Hardy, Nicola Normanno, David S Salomon, Mary J C Hendrix.   

Abstract

Cripto-1 (CR-1) protein function differs according to cellular or extracellular expression. In this study, we explore the significance of cell surface CR-1 expression in human melanoma cells. Cell surface CR-1-expressing human melanoma cells (CR1-CS+) were selected by fluorescence-activated cell sorting (FACS) and grown in vitro and in vivo in nude mice to study their growth characteristics. The CR1-CS+ melanoma cells were found to express increased levels of Oct4, MDR-1 and activated c-Src compared with cells lacking this subpopulation (CR1-CS-) or unsorted cells, used as control. CR1-CS+ show reduced proliferation rates and diminished spherical colony formation compared with control cells when cultured in vitro. Orthotopic injections of CR1-CS+ in nude mice formed slow growing tumors with histologic variability across different areas of the CR1-CS+ xenografts. CR-1-expressing cells from first generation CR1-CS+ tumors showed significantly increased tumor-forming rate and aggressiveness following subsequent transplants in nude mice. These data demonstrate that within a heterogeneous melanoma cell population there resides a slow proliferating, cell surface CR-1-expressing subpopulation capable of giving rise to a fast growing, aggressive progeny that may contribute to disease recurrence and progression.

Entities:  

Keywords:  Cripto-1; aggressiveness; melanoma; recurrence; target; tumorigenicity

Mesh:

Substances:

Year:  2013        PMID: 23574716      PMCID: PMC3674072          DOI: 10.4161/cc.24601

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  24 in total

1.  Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells.

Authors:  Kazuhide Watanabe; Matthew J Meyer; Luigi Strizzi; Joseph M Lee; Monica Gonzales; Caterina Bianco; Tadahiro Nagaoka; Shahram S Farid; Naira Margaryan; Mary J C Hendrix; Barbara K Vonderhaar; David S Salomon
Journal:  Stem Cells       Date:  2010-08       Impact factor: 6.277

Review 2.  Role of Cripto-1 in stem cell maintenance and malignant progression.

Authors:  Caterina Bianco; Maria Cristina Rangel; Nadia P Castro; Tadahiro Nagaoka; Kelly Rollman; Monica Gonzales; David S Salomon
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

3.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.

Authors:  Christian W Scharenberg; Michael A Harkey; Beverly Torok-Storb
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

4.  Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype.

Authors:  Katharine M Hardy; Dawn A Kirschmann; Elisabeth A Seftor; Naira V Margaryan; Lynne-Marie Postovit; Luigi Strizzi; Mary J C Hendrix
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

Review 5.  Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis.

Authors:  Luigi Strizzi; Caterina Bianco; Nicola Normanno; David Salomon
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

6.  ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.

Authors:  Natasha Y Frank; Armen Margaryan; Ying Huang; Tobias Schatton; Ana Maria Waaga-Gasser; Martin Gasser; Mohamed H Sayegh; Wolfgang Sadee; Markus H Frank
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

7.  A tumorigenic subpopulation with stem cell properties in melanomas.

Authors:  Dong Fang; Thiennga K Nguyen; Kim Leishear; Rena Finko; Angela N Kulp; Susan Hotz; Patricia A Van Belle; Xiaowei Xu; David E Elder; Meenhard Herlyn
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

Review 8.  Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Angela R Hess; Richard E B Seftor
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

9.  Cripto-independent Nodal signaling promotes positioning of the A-P axis in the early mouse embryo.

Authors:  Giovanna L Liguori; Ana Cristina Borges; Daniela D'Andrea; Annamaria Liguoro; Lisa Gonçalves; Ana Marisa Salgueiro; M Graziella Persico; José Antonio Belo
Journal:  Dev Biol       Date:  2007-12-31       Impact factor: 3.582

10.  Expression and functional role of CRIPTO-1 in cutaneous melanoma.

Authors:  A De Luca; L Lamura; L Strizzi; C Roma; A D'Antonio; N Margaryan; G Pirozzi; M-Y Hsu; G Botti; E Mari; M J C Hendrix; D S Salomon; N Normanno
Journal:  Br J Cancer       Date:  2011-08-23       Impact factor: 7.640

View more
  12 in total

1.  Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells In vitro and In vivo.

Authors:  Nadia P Castro; Maria C Rangel; Anand S Merchant; Gabriel MacKinnon; Frank Cuttitta; David S Salomon; Young S Kim
Journal:  Cancer Prev Res (Phila)       Date:  2019-01-24

2.  Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer.

Authors:  Chun-Hua Xu; Zhi-Hong Sheng; Hui-Di Hu; Ke-Ke Hao; Qing-Bo Wang; Li-Ke Yu
Journal:  Tumour Biol       Date:  2014-05-29

Review 3.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

4.  CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.

Authors:  Stéphane Terry; Ihsan Y El-Sayed; Damien Destouches; Pascale Maillé; Nathalie Nicolaiew; Guillaume Ploussard; Fannie Semprez; Cynthia Pimpie; Himisha Beltran; Arturo Londono-Vallejo; Yves Allory; Alexandre de la Taille; David S Salomon; Francis Vacherot
Journal:  Oncotarget       Date:  2015-05-20

5.  Autoregulation and heterogeneity in expression of human Cripto-1.

Authors:  Pojul Loying; Janvie Manhas; Sudip Sen; Biplab Bose
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

6.  New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding.

Authors:  Annalia Focà; Luca Sanguigno; Giuseppina Focà; Luigi Strizzi; Roberta Iannitti; Rosanna Palumbo; Mary J C Hendrix; Antonio Leonardi; Menotti Ruvo; Annamaria Sandomenico
Journal:  Int J Mol Sci       Date:  2015-09-07       Impact factor: 5.923

7.  Liver-specific over-expression of Cripto-1 in transgenic mice promotes hepatocyte proliferation and deregulated expression of hepatocarcinogenesis-related genes and signaling pathways.

Authors:  Yu Liu; Yan-Qing Li; Shi-Hao Huang; Yong-Long Li; Jia-Wei Xia; Jun-Shuang Jia; Fang Wei; Jia-Hong Wang; Guan-Qi Dai; Yu-Cai Wang; Xiao-Yan Li; Liu-Xin Han; Xiao-Ling Zhang; Xu-Dong Xiang; Wen-Tao Zhao; Dong Xiao; Xiao-Lin Lin
Journal:  Aging (Albany NY)       Date:  2021-09-13       Impact factor: 5.682

8.  CD271 is an imperfect marker for melanoma initiating cells.

Authors:  Yann Cheli; Vanessa F Bonnazi; Arnaud Jacquel; Maryline Allegra; Gian Marco De Donatis; Philippe Bahadoran; Corine Bertolotto; Robert Ballotti
Journal:  Oncotarget       Date:  2014-07-30

9.  Cripto-1 vaccination elicits protective immunity against metastatic melanoma.

Authors:  M A Ligtenberg; K Witt; F Galvez-Cancino; A Sette; A Lundqvist; A Lladser; R Kiessling
Journal:  Oncoimmunology       Date:  2016-01-08       Impact factor: 8.110

10.  Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma.

Authors:  Qiang Liu; Xiang Cui; Xi Yu; Bai-Shi-Jiao Bian; Feng Qian; Xu-Gang Hu; Cheng-Dong Ji; Lang Yang; Yong Ren; Wei Cui; Xia Zhang; Peng Zhang; Ji Ming Wang; You-Hong Cui; Xiu-Wu Bian
Journal:  Mol Cancer       Date:  2017-04-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.